Filing Flows

Filing Flows › Health Care › Lifecore Biomedical (LFCR)

Lifecore Biomedical (LFCR) earnings and revenue breakdown

Latest: Q1 FY27 · 10-Q filed Nov 4, 2026 · Lifecore Biomedical (LFCR) Q1 FY27 earnings results →

Q1 FY27 Revenue down 19% year over year to $25.3M · 158¢ of every $1 of revenue lost · operating margin -3.5%

Lifecore Biomedical made $25.3M in Q1 FY27 (-19% Y/Y): CDMO $17.8M, HA manufacturing $7.5M. Operating margin -3.5%, net loss $40.1M. See where every dollar goes — costs, profit and cash — as a Sankey from the 10-Q filed Nov 4, 2026.

Revenue$25.3M
Year over year-19%
Operating margin-3.5%
Net earnings−$40.1M
Operating cash flow$6.9M

Drawing the Sankey…

Open the interactive Sankey → click any line for what the company wrote about it, compare Y/Y and Q/Q, export as PNG or PDF

What changed this quarter

Revenue was $25.3M in Q1 FY27, down 19% year over year and down 26% from the previous quarter. CDMO was the largest line at 70% of revenue. CDMO lost $4.0M year over year (down 18%), 69% of the total change.

Gross margin was 27.0%, up 1.9 points from Q1 FY26. Operating costs exceeded revenue by $894K, an operating margin of -3.5%. Operating expenses fell 29% while revenue fell 19%. The quarter ended with a net loss of $40.1M, wider than the previous quarter's $6.2M loss. Net interest and other expense of $39.1M was the main reason.

Operating cash flow was $6.9M (up 294% year over year). Non-cash charges added back $2.4M of depreciation and $1.7M of share-based compensation. Working capital and other items added $42.9M. Capital expenditures of $912K left free cash flow of $6.0M.

Quarterly history

Lifecore Biomedical revenue by quarterLifecore Biomedical revenue by quarter$32.6MQ2 FY25$35.2MQ3 FY25$36.4MQ4 FY25$31.1MQ1 FY26$23.2MQ3 FY26$34.2MQ1 FY27$25.3MQ1 FY27
Lifecore Biomedical net earnings by quarterLifecore Biomedical net earnings by quarter−$6.6MQ2 FY25−$14.8MQ3 FY25−$1.1MQ4 FY25−$10.0MQ1 FY26−$15.0MQ3 FY26−$6.2MQ1 FY27−$40.1MQ1 FY27
QuarterFormFiledRevenueY/YOp. marginNet earningsOp. cash flow
Q1 FY2710-QNov 4, 2026$25.3M-19%-3.5%−$40.1M$6.9M
Q1 FY2710-QAug 5, 2026$34.2M—7.5%−$6.2M−$2.2M
Q3 FY2610-QMay 6, 2026$23.2M—-20.1%−$15.0M$4.7M
Q1 FY2610-QNov 6, 2025$31.1M—-9.9%−$10.0M$1.8M
Q4 FY2510-KAug 7, 2025$36.4M-4%14.6%−$1.1M$5.3M
Q3 FY2510-QApr 3, 2025$35.2M-2%-25.7%−$14.8M$1.2M
Q2 FY2510-QJan 2, 2025$32.6M+8%-6.0%−$6.6M−$6.1M

Charts

Lifecore Biomedical: revenue growth, year over year and quarter over quarterLifecore Biomedical: revenue growth, year over year and quarter over quarterY/YQ/Q+8%Q2 FY25-2%+8%Q3 FY25-4%+4%Q4 FY25-15%Q1 FY26-25%Q3 FY26+47%Q1 FY27-19%-26%Q1 FY27
Latest (Q1 FY27): Y/Y -19%, Q/Q -26%.
Lifecore Biomedical: where the cash came from (+) and went (−), FY25Lifecore Biomedical: where the cash came from (+) and went (−), FY25Shares issued$23.9MNet borrowing (+) / repaid (−)−$17.2MCapital spending−$13.4MAsset & business sales$7.0MTaxes on employees’ shares−$1.3MOther financing$1.0MOperating cash flow−$206KCash drawn (+) / kept (−)$197K
From the cash-flow statement as filed (SEC XBRL). Cash is fungible: the bars do not say which dollar paid for what.
Lifecore Biomedical: profit against cash, quarter by quarterLifecore Biomedical: profit against cash, quarter by quarterNet incomeOperating cash flow−$16.2M−$613KQ1 FY25−$6.6M−$6.1MQ2 FY25−$14.8M$1.2MQ3 FY25−$1.1M$5.3MQ4 FY25−$10.0M$1.8MQ1 FY26−$15.0M$4.7MQ3 FY26−$6.2M−$2.2MQ1 FY27−$40.1M$6.9MQ1 FY27
Latest (Q1 FY27): Net income −$40.1M, Operating cash flow $6.9M.
Lifecore Biomedical: diluted shares by fiscal yearLifecore Biomedical: diluted shares by fiscal year29MFY2029MFY2129MFY2230MFY2337MFY2435MFY25
+19.4% since FY20: more shares outstanding (issuance, stock pay).
Lifecore Biomedical: long-term debt falling due (FY25)Lifecore Biomedical: long-term debt falling due (FY25)$3.4M2026$967K2027$1.0M2028$175M2029$1.1M2030$7.3MLater
Cash $8.3M, short-term investments —, long-term debt $130M at 2025-05-25.
Lifecore Biomedical in its industry: growth against margin (225 companies, SIC 2834)Lifecore Biomedical in its industry: growth against margin (225 companies, SIC 2834)revenue growth, year over year →↑ operating marginmedian +11%median -50%JNJLLYMRKABBVPFEBMYABTREGNTEVAVTRSVRTXBHCZTSONCOGNALNYELANJAZZBMRNPRGOAMRXUTHRRPRXNRIXINSMKeenova Therapeutics plcALKSMDGLPAHCSRPTPTCTINDVBBIOACADCORTPBHANIPKNSAPTGXHRMYIONSAXSMTGTXSUPNTVTXCOLLVREOFAMPHMIRMPCRXRARELQDAARQTIRWDARDXNATRXNCREBSZLABXERSINVACRMDMNKDRYTMURGNPHATAUPHSNDXRIGLLGNDEOLSARWRPGENHROWVNDAOPKSDGRGERNETONAGIOPBYITNGXCYRXCYTKMRVIORGONUVBLFVNSIGAKROSAMRNZVRASPRYHRTXAKBABCYCKPTIGYREMGNXELTPSEPNVRDNCrinetics Pharmaceuticals, Inc.VSTMKURATBPHLABADCTNAMSFBIOXLODERMARCTRMTIAYTUFHTXENTATNXPOCULASMBWVEAPMDBFRIABEOSTOKLXRXCAPRIDYANKTRZOMDFINBPJANXSBFMGOSSETSTRCUSCPIXLIFDCUEAQSTPRAXWHWKVERUEMMAGENBVRCACELUQUREZYMEEQABCLIMNMKYNBAKTSRNACVSICNTBTRAWISCOEVFMTVRDLPCNCAMPAtaiBeckley Inc.CTMXALMSPMHSACRSVTGNROIVKRROJAGXENSCKRSAABUSPRPHSTTKCPHITRDATXMDGOVXNWBOBIOEUPBIRDOVIDSPRBXBIOPRTAMCRBARVNMNOVSLNIGCBIOALGVNDNTHCPMDSPRORFLCOYASCYXBFRGSXTPBTAIQHCWBSERYARWRNACRGBPAVTXCLNNNTHIHINDAAGHALTONCOCRVOSKVIBOLTBDPTLYELIBOPULMLFCR (-19%, -4%)
Pharmaceutical Preparations; dot size is quarterly revenue; dashed lines are the industry's medians.

Interactive views

The same charts as the app — open one to draw it.

💵Where each $1 goesinteractive

Loading the interactive chart…

🌏Named in Asian annual reportsinteractive

Loading the interactive chart…

🔄Rotation against the market and its industry (RRG)interactive

Loading the interactive chart…

🔍Earnings qualityinteractive

Loading the interactive chart…

⚖️Fair value by methodinteractive

Loading the interactive chart…

🔭Outlook & guidanceinteractive

Loading the interactive chart…

📈Investments: gains and what it boughtinteractive

Loading the interactive chart…

🏭Its industry’s money flow (input-output)interactive

Loading the interactive chart…

About Lifecore Biomedical

Lifecore Biomedical, Inc. and its subsidiaries (“Lifecore”, the “Company”, “we” or “us”), located in Chaska, Minnesota, is a fully integrated contract development and manufacturing organization (“CDMO”) that offers highly differentiated clinical and commercial capabilities in the development, cGMP manufacturing and aseptic filling of complex formulations and highly viscous sterile injectable pharmaceutical drug or medical device products in syringes, vials and cartridges, across a wide variety of modalities. Lifecore has become a leading U.S. manufacturer of pharmaceutical-grade, non-animal-sourced hyaluronic acid (“HA”) using our proprietary, fermentation-based HA process that we developed in 1981.

In its own words, from its 10-K, filed Aug 7, 2025.

Lifecore Biomedical against its Pharmaceutical Preparations peers

The largest companies of the same SEC industry, each at its latest quarter. Revenue growth: -19% against the peers' median +7%. Operating margin: -3.5% against the peers' median 20.4%.

CompanyQuarterRevenueY/YOp. margin
LFCR Lifecore BiomedicalQ1 FY27$25.3M-19%-3.5%
JNJ Johnson & JohnsonQ3 2026$25.4B+6%0.1%
LLY ELI LillyQ3 2026$24.4B+39%34.5%
MRK MerckQ3 2026$18.1B+5%30.7%
ABBV AbbVieQ3 2026$17.4B+10%36.0%
PFE PfizerQ3 2026$16.6B-0.4%20.4%
BMY Bristol Myers SquibbQ3 2026$13.1B+7%19.4%
ABT Abbott LaboratoriesQ3 2026$13.0B+14%10.4%
REGN Regeneron PharmaceuticalsQ3 2026$5.1B+36%40.0%

Source: Lifecore Biomedical 10-Q on SEC EDGAR · CIK 1005286 · Pharmaceutical Preparations

Guidance and outlook

Lifecore Biomedical: what its forward-looking statements are about (10-Q filed 2026-11-04)Lifecore Biomedical: what its forward-looking statements are about (10-Q filed 2026-11-04)Other2People1Costs1
4 statements; tone +0.50 (−1 all cautious, +1 all confident); 2 hedged.
Lifecore Biomedical: outlook statements against the filing beforeLifecore Biomedical: outlook statements against the filing beforeConfident2

13F: who owns LFCR and who is buying

Largest holders of LFCR (13F)Largest holders of LFCR (13F)Wynnefield Capital$24.7MLegion Partners Asset Management,…$23.4MGreenhaven Road Investment Manage…$16.8M325 Capital LLC$15.2MVanguard Group$13.7MBlackRock$10.6MVanguard Capital Management LLC$6.8MGeode Capital Management, LLC$4.5MMorgan Stanley$4.0MState Street$3.5M
Funds' net buying of LFCR by quarter (13F)Funds' net buying of LFCR by quarter (13F)−$5.1M2024-09$23.7M2024-12−$2.0M2025-03$2.1M2025-06−$3.4M2025-09$3.3M2025-12$1.1M2026-03$1.6M2026-06
Value of shares 13F filers added minus the value they sold, each quarter (quarters with most filings in).

More on LFCR

History

Every quarter: Q1 FY27 results · Q1 FY27 results · Q3 FY26 results · Q1 FY26 results · Q4 FY25 results · Q3 FY25 results · Q2 FY25 results

Compare LFCR with

中文版：Lifecore Biomedical（LFCR）财报

Español · Français